Role of vitamin D in the physiopathology of neurodegenerative diseases;Rôle de la vitamine D dans la physiopathologie des maladies neurodégénératives

Biologie Aujourd'hui

Volumn 208, Issue 1, 2014, Pages 77-88

  Millet, Pascal ^a   Landel, Véréna ^a   Virard, Isabelle ^a   Morello, Maria ^a,b   Féron, François ^a  

^a Mediterranée University   (France)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Nervous system; Neurodegenerative diseases; Neuroprotection; Therapy; Vitamin D

Indexed keywords

NEUROPROTECTIVE AGENT; VITAMIN D;

ANIMAL; COGNITION DISORDERS; COMPLICATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMAN; IMMUNOLOGY; METABOLISM; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION RESPONSE; SKIN; SUNLIGHT; VITAMIN D DEFICIENCY;

ANIMALS; COGNITION DISORDERS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; SKIN; SUNLIGHT; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84903301677     PISSN: 21050678     EISSN: 21050686     Source Type: Journal    
DOI: 10.1051/jbio/20140007     Document Type: Article

References (136)

1. Acheson E.D., Bachrach C.A., Wright F.M., Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand Suppl, 1960, 35, 132-147.
2. Adzemovic M.Z., Zeitelhofer M., Hochmeister S., Gustafsson S.A., Jagodic M., Efficacy of vitamin D in treating multiple sclerosis-like neuroinflammation depends on developmental stage. Exp Neurol, 2013, 249, 39-48.
3. Agranoff B.W., Goldberg D., Diet and the geographical distribution of multiple sclerosis. Lancet, 1974, 2, 1061-1066.
4. Ajdacic-Gross V., Wang J., Gutzwiller F., Season of birth in amyotrophic lateral sclerosis. Eur J Epidemiol, 1998, 14, 359-361.
5. Almeras L., Eyles D., Benech P., Laffite D., Villard C., Patatian A., Boucraut J., Mackay-Sim A., McGrath J., Féron F., Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics, 2007, 7, 769-780.
6. Annweiler C., Souberbielle J.C., Schott A.M., de Decker L., Berrut G., Beauchet O., [Vitamin D in the elderly: 5 points to remember]. Geriatr Psychol Neuropsychiatr Vieil, 2011, 9, 259-267.
7. Annweiler C., Herrmann F.R., Fantino B., Brugg B., Beauchet O., Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol, 2012 a, 25, 121-127.
8. Annweiler C., Rolland Y., Schott A.M., Blain H., Vellas B., Beauchet O., Serum vitamin D deficiency as a predictor of incident non-Alzheimer dementias: a 7-year longitudinal study. Dement Geriatr Cogn Disord, 2012 b, 32, 273-278.
9. Annweiler C., Fantino B., Schott A.M., Krolak-Salmon P., Allali G., Beauchet O., Vitamin D insufficiency and mild cognitive impairment: cross-sectional association. Eur J Neurol, 2012 c, 19, 1023-1029.
10. Annweiler C., Brugg B., Peyrin J.M., Bartha R., Beauchet O., Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. Neurobiol Aging, 2013, 35, 331-335.
11. Auer D.P., Schumann E.M., Kumpfel T., Gossl C., Trenkwalder C., Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol, 2000, 47, 276-277.
12. Baas D., Prufer K., Ittel M.E., Kuchler-Bopp S., Labourdette G., Sarliève L.L., Brachet P., Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3). Glia, 2000, 31, 59-68.
13. Banwell B., Bar-Or A., Arnold D.L., Sadovnick D., Narayanan S., McGowan M., O'Mahony J., Magalhaes S., Hanwell H., Vieth R., Tellier R., Vincent T., Disanto G., Ebers G., Wambera K., Connolly M.B., Yager J., Mah J.K., Booth F., Sebire G., Callen D., Meaney B., Dilenge M.E., Lortie A., Pohl D., Doja A., Venketaswaran S., Levin S., Macdonald E.A., Meek D., Wood E., Lowry N., Buckley D., Yim C., Awuku M., Cooper P., Grand'maison F., Baird J.B., Bhan V., Marrie R.A., Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol, 2011, 10, 436-445.
14. Baxter A.G., Smyth M.J., The role of NK cells in autoimmune disease. Autoimmunity, 2002, 35, 1-14.
15. Beecham G.W., Martin E.R., Li Y.J., Slifer M.A., Gilbert J.R., Haines J.L., Pericak-Vance M.A., Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet, 2009, 84, 35-43.
16. Betemps E.J., Buncher C.R., Birthplace as a risk factor in motor neurone disease and Parkinson's disease. Int J Epidemiol, 1993, 22, 898-904.
17. 3 on collagen type I, osteopontin, and osteocalcin gene expression in chicken osteoblasts. J Cell Biochem, 1995, 57, 440-451.
18. Buell J.S., Dawson-Hughes B., Vitamin D and neurocognitive dysfunction: preventing "D"ecline? Mol Aspects Med, 2008, 29, 415-422.
19. Butler M.W., Burt A., Edwards T.L., Zuchner S., Scott W.K., Martin E. R., Vance J.M., Wang L., Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet, 2011, 75, 201-210.
20. Camu W., Tremblier B., Plassot C., Alphandery S., Salsac C., Pageot N., Juntas-Morales R., Scamps F., Daurès J.P., Raoul C., Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol Aging, 2014, 35, 1198-1205.
21. 3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA, 1996, 93, 7861-7864.
22. 3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol, 1998, 160, 5314-5319.
23. Cantorna M.T., Zhao J., Yang L., Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. Proc Nutr Soc, 2011, 71, 62-66.
24. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., Steinman L., The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science, 2001, 294, 1731-1735.
25. 3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One, 2010, 5, e12925.
26. Chio A., Cucatto A., Calvo A., Terreni A.A., Magnani C., Schiffer D., Amyotrophic lateral sclerosis among the migrant population to Piemonte, northwestern Italy. J Neurol, 1999, 246, 175-180.
27. Constans T., Mondon K., Annweiler C., Hommet C., [Vitamin D and cognition in the elderly]. Psychol Neuropsychiatr Vieil, 2010, 8, 255-262.
28. Cui X., Pelekanos M., Liu P.Y., Burne T.H., McGrath J.J., Eyles D.W., The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience, 2013, 236, 77-87.
29. DeLuca G.C., Kimball S.M., Kolasinski J., Ramagopalan S.V., Ebers G.C., Review: the role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol, 2013, 39, 458-484.
30. Desjardins M., ER-mediated phagocytosis: a new membrane for new functions. Nat Rev Immunol, 2003, 3, 280-291.
31. Disanto G., Berlanga A.J., Handel A.E., Para A.E., Burrell A.M., Fries A., Handunnetthi L., De Luca G.C., Morahan J.M., Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis, 2010, 2011, 932351.
32. Dobson R., Giovannoni G., Ramagopalan S., The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry, 2012, 84, 427-432.
33. Dursun E., Gezen-Ak D., Yilmazer S., A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-beta and preventing the amyloid-beta induced alterations by vitamin D in cortical neurons. J Alzheimers Dis, 2010, 23, 207-219.
34. Dursun E., Gezen-Ak D., Yilmazer S., Beta amyloid suppresses the expression of the vitamin D receptor gene and induces the expression of the vitamin D catabolic enzyme gene in hippocampal neurons. Dement Geriatr Cogn Disord, 2013, 36, 76-86.
35. Esparza M.L., Sasaki S., Kesteloot H., Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol, 1995, 142, 733-737.
36. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., Tangpricha V., Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol, 2008, 65, 1348-1352.
37. Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J., Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat, 2005, 29, 21-30.
38. Eyles D., Almeras L., Benech P., Patatian A., Mackay-Sim A., McGrath J., Féron F., Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J Steroid Biochem Mol Biol, 2007, 103, 538-545.
39. Fang F., Valdimarsdottir U., Bellocco R., Ronnevi L.O., Sparen P., Fall K., Ye W., Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch Neurol, 2009, 66, 515-519.
40. Fawcett J., Skegg D.C., Geographic distribution of MS in New Zealand: evidence from hospital admissions and deaths. Neurology, 1988, 38, 416-418.
41. Fernandes de Abreu D.A., Babron M.C., Rebeix I., Fontenille C., Yaouanq J., Brassat D., Fontaine B., Clerget-Darpoux F., Jehan F., Féron F., Season of birth and not vitamin D receptor promoter polymorphisms is a risk factor for multiple sclerosis. Mult Scler, 2009, 15, 1146-1152.
42. Fernandes de Abreu D.A., Landel V., Barnett A.G., McGrath, J., Eyles D., Féron F., Prenatal vitamin d deficiency induces an early and more severe experimental autoimmune encephalomyelitis in the second generation. Int J Mol Sci, 2012, 13, 10911-10919.
43. Fukazawa T., Kikuchi S., Niino M., Yabe I., Miyagishi R., Fukaura H., Hamada T., Tashiro K., [Susceptibility genes for multiple sclerosis]. Nihon Rinsho, 2003, 61, 1311-1316.
44. 3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res, 1997, 45, 255-267.
45. 3. Glia, 1998, 22, 282-294.
46. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., Wion D., New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab, 2002, 13, 100-105.
47. 3 leads to early effects within the central nervous system. Acta Neuropathol, 2003, 105, 438-448.
48. Gezen-Ak D., Dursun E., Ertan T., Hanagasi H., Gurvit H., Emre M., Eker E., Ozturk M., Engin F., Yilmazer S., Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J Exp Med, 2007, 212, 275-282.
49. Gezen-Ak D., Dursun E., Bilgic B., Hanagasi H., Ertan T., Gurvit H., Emre M., Eker E., Ulutin T., Uysal O., Yilmazer S., Vitamin D receptor gene haplotype is associated with late-onset Alzheimer's disease. Tohoku J Exp Med, 2012 a, 228, 189-196.
50. Gezen-Ak D., Dursun E., Yilmazer S., Vitamin D inquiry in hippocampal neurons: consequences of vitamin D-VDR pathway disruption on calcium channel and the vitamin D requirement. Neurol Sci, 2012 b, 34, 1453-1458.
51. Gezen-Ak D., Yilmazer S., Dursun E., Why Vitamin D in Alzheimer's Disease? The Hypothesis. J Alzheimers Dis, 2014, 40, 257-269.
52. Giovannoni G., Ebers G., Multiple sclerosis: the environment and causation. Curr Opin Neurol, 2007, 20, 261-268.
53. Goldberg P., Fleming M.C., Picard E.H., Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses, 1986, 21, 193-200.
54. Grimm M.O., Lehmann J., Mett J., Zimmer V.C., Grosgen S., Stahlmann C.P., Hundsdorfer B., Haupenthal V.J., Rothhaar T.L., Herr C., Bals R., Grimm H.S., Hartmann T., Impact of Vitamin D on Amyloid Precursor Protein Processing and Amyloid-beta Peptide Degradation in Alzheimer's Disease. Neurodegener Dis, 2013, 13, 75-81.
55. 3 selectively and reversibly impairs T helper-cell CNS localization. Proc Natl Acad Sci USA, 2013, 110, 21101-21106.
56. Hammond S.R., McLeod J.G., Macaskill P., English D.R., Multiple sclerosis in Australia: prognostic factors. J Clin Neurosci, 2000, 7, 16-19.
57. Handunnetthi L., Ramagopalan S.V., Ebers G.C., Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology, 2010, 74, 1905-1910.
58. Hayes C.E., Cantorna M.T., DeLuca H.F., Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med, 1997, 216, 21-27.
59. Hernan M.A., Olek M.J., Ascherio A., Geographic variation of MS incidence in two prospective studies of US women. Neurology, 1999, 53, 1711-1718.
60. Ibi M., Sawada H., Nakanishi M., Kume T., Katsuki H., Kaneko S., Shimohama S., Akaike A., Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology, 2001, 40, 761-771.
61. 3 enhances cerebral clearance of human amyloid-beta peptide(1-40) from mouse brain across the blood-brain barrier. Fluids Barriers CNS, 2011, 8, 20.
62. Joshi S., Pantalena C., Liu X.K., Gaffen S.L., Liu H., Rohowsky-Kochan C., Ichiyama K., Yoshimura, L., Steinman L., Christakos S., Youssef S., 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol, 2011, 31, 3653-3669.
63. Kalueff A.V., Tuohimaa P., Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care, 2007, 10, 12-19.
64. Kampman M.T., Wilsgaard T., Mellgren S.I., Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol, 2007, 254, 471-477.
65. Keeney J.T., Forster S., Sultana R., Brewer L.D., Latimer C.S., Cai J., Klein J.B., Porter N.M., Allan D., Butterfield Dietary vitamin D deficiency in rats from middle to old age leads to elevated tyrosine nitration and proteomics changes in levels of key proteins in brain: implications for low vitamin D-dependent age-related cognitive decline. Free Radic Biol Med, 2013, 65, 324-334.
66. Kim J.S., Kim Y.I., Song C., Yoon I., Park J.W., Choi Y.B., Kim H.T., Lee K.S., Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. J Korean Med Sci, 2005, 20, 495-498.
67. King H., Rosenheim O., Webster T.A., Vitamin D from sterols of mummified Egyptian brain. Biochem J, 1929, 23, 166-167.
68. Kurtzke J.F., Hyllested K., Arbuckle J.D., Bronnum-Hansen H., Wallin M.T., Heltberg A., Jacobsen H., Olsen A., Eriksen L.S., Multiple sclerosis in the Faroe Islands. 7. Results of a case control questionnaire with multiple controls. Acta Neurol Scand, 1997, 96, 149-157.
69. Lehmann D.J., Refsum H., Warden D.R., Medway C., Wilcock G.K., Smith A.D., The vitamin D receptor gene is associated with Alzheimer's disease. Neurosci Lett, 2011, 504, 79-82.
70. Leibowitz U., Sharon D., Alter M., Geographical considerations in multiple sclerosis. Brain, 1968, 91, 37-52.
71. 3 suppresses TLR8 expression and TLR8-mediated inflammatory responses in monocytes in vitro and experimental autoimmune encephalomyelitis in vivo. PLoS One, 2013, 8, e58808.
72. Llewellyn D.J., Langa K.M., Lang I.A., Serum 25-hydroxyvitamin D concentration and cognitive impairment. J Geriatr Psychiatry Neurol, 2009, 22, 188-195.
73. Lux W.E., Kurtzke J.F., Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis. Neurology, 1987, 37, 467-471.
74. Mattner F., Smiroldo S., Galbiati F., Muller M., Di Lucia P., Poliani P.L., Martino G., Panina-Bordignon P., Adorini L., Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol, 2000, 30, 498-508.
75. Mattock C., Marmot M., Stern G., Could Parkinson's disease follow intra-uterine influenza? A speculative hypothesis. J Neurol Neurosurg Psychiatry, 1988, 51, 753-756.
76. 3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis. Eur J Immunol, 2011, 41, 822-832.
77. McCann J.C., Ames B.N., Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction ? FASEB J, 2008, 22, 982-1001.
78. McGuigan C., McCarthy A., Quigley C., Bannan L., Hawkins S.A., Hutchinson M., Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. J Neurol Neurosurg Psychiatry, 2004, 75, 572-576.
79. McLeod J.G., Hammond S.R., Hallpike J.F., Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust, 1994, 160, 117-122.
80. Meehan T.F., DeLuca H.F., The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys, 2002, 408, 200-204.
81. 3 promotes the recovery of amyloid-beta phagocytosis by Alzheimer's disease macrophages. J Alzheimers Dis, 2011, 29, 51-62.
82. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A., Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 2006, 296, 2832-2838.
83. 3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res, 2006, 83, 1299-1309.
84. Nashold F.E., Hoag K.A., Goverman J., Hayes C.E., Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol, 2001, 119, 16-29.
85. 3 metabolism and receptor expression. J Immunol, 2009, 183, 3672-3681.
86. Nashold F.E., Nelson C.D., Brown L.M., Hayes C.E., One calcitriol dose transiently increases Helios + FoxP3 + T cells and ameliorates autoimmune demyelinating disease. J Neuroimmunol, 2013, 263, 64-74.
87. 3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J Neuropathol Exp Neurol, 1996, 55, 904-914.
88. 3 24-hydroxylase gene in glial cells. Neuroreport, 1993, 5, 255-257.
89. 3 by rat brain macrophages in vitro. J Neurosci Res, 1994, 38, 214-220.
90. 3 includes genes limiting the progression of neurodegenerative diseases. J Alzheimers Dis, 2013, 35, 553-564.
91. + T cells is induced by immunosuppressive drugs and inhibited by Th1- and Th2-inducing cytokines. Immunol Lett, 2003, 85, 135-139.
92. Okuda Y., Nakatsuji Y., Fujimura H., Esumi H., Ogura T., Yanagihara T., Sakoda S., Expression of the inducible isoform of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis. J Neuroimmunol, 1995, 62, 103-112.
93. Orton S.M., Wald L., Confavreux C., Vukusic S., Krohn J.P., Ramagopalan S.V., Herrera B.M., Sadovnick A.D., Ebers G.C., Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology, 2012, 76, 425-431.
94. 3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dement Geriatr Cogn Disord, 2008, 25, 539-543.
95. 3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res, 2007, 85, 2480-2490.
96. Puchacz E., Stumpf W.E., Stachowiak E.K., Stachowiak M.K., Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res Mol Brain Res, 1996, 36, 193-196.
97. Querfurth H.W., LaFerla F.M., Alzheimer's disease. N Engl J Med, 2010, 362, 329-344.
98. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., Lincoln M.R., Orton S.M., Dyment D.A., Deluca G.C., Herrera B.M., Chao M.J., Sadovnick A.D., Ebers G.C., Knight J.C., Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet, 2009, 5, e1000369.
99. Reinholt F.P., Hultenby K., Oldberg A., Heinegard D., Osteopontin-a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA, 1990, 87, 4473-4475.
100. Rossom R.C., Espeland M.A., Manson J.E., Dysken M.W., Johnson K.C., Lane D.S., LeBlanc E.S., Lederle F.A., Masaki K.H., Margolis K.L., Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative. J Am Geriatr Soc, 2012, 60, 2197-2205.
101. Sanchez B., Lopez-Martin E., Segura C., Labandeira-Garcia J.L., Perez-Fernandez R., 1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. Brain Res Mol Brain Res, 2002, 108, 143-146.
102. Schmidt H., Williamson D., Ashley-Koch A., HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol, 2007, 165, 1097-1109.
103. Sejvar J.J., Holman R.C., Bresee J.S., Kochanek K.D., Schonberger L.B., Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology, 2005, 25, 144-152.
104. Shinpo K., Kikuchi S., Sasaki H., Moriwaka F., Tashiro K., Effect of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4- phenylpyridine. J Neurosci Res, 2000, 62, 374-382.
105. Slinin Y., Paudel M.L., Taylor B.C., Fink H.A., Ishani A., Canales M. T., Yaffe K., Barrett-Connor E., Orwoll E.S., Shikany J.M., Leblanc E.S., Cauley J.A., Ensrud K.E., 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology, 2009, 74, 33-41.
106. Slinin Y., Paudel M., Taylor B.C., Ishani A., Rossom R., Yaffe K., Blackwell T., Lui L.Y., Hochberg M., Ensrud K.E., Association between serum 25(OH) vitamin D and the risk of cognitive decline in older women. J Gerontol A Biol Sci Med Sci, 2012, 67, 1092-1098.
107. Smith M.P., Fletcher-Turner A., Yurek D.M., Cass W.A., Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res, 2006, 31, 533-539.
108. 3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci, 2011, 311, 44-49.
109. 3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry, 2012, 83, 565-571.
110. 3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol, 2005, 175, 4119-4126.
111. 3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics, 2004, 18, 141-151.
112. 3 -mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol, 2006, 177, 6030-6037.
113. Stepkowski S.M., Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med, 2000, 2, 1-23.
114. Stromnes I.M., Goverman J.M., Osteopontin-induced survival of T cells. Nat Immunol, 2007, 8, 19-20.
115. 3. Science, 1982, 215, 1403-1405.
116. Sutherland J.M., Tyrer J.H., Eadie M.J., The prevalence of multiple sclerosis in Australia. Brain, 1962, 85, 149-164.
117. Sutherland M.K., Somerville M.J., Yoong L.K., Bergeron C., Haussler M. R., McLachlan D.R., Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res Mol Brain Res, 1992, 13, 239-250.
118. Taghizadeh M., Djazayery A., Salami M., Eshraghian M.R., Zavareh S.A., Vitamin-D-free regimen intensifies the spatial learning deficit in Alzheimer's disease. Int J Neurosci, 2010, 121, 16-24.
119. Takahashi K., Miyake S., Kondo T., Terao K., Hatakenaka M., Hashimoto S., Yamamura T., Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest, 2001, 107, R23-29.
120. Takahashi K., Aranami T., Endoh M., Miyake S., Yamamura T., The regulatory role of natural killer cells in multiple sclerosis. Brain, 2004, 127, 1917-1927.
121. Templer D.I., Trent N.H., Spencer D.A., Trent A., Corgiat M.D., Mortensen P.B., Gorton M., Season of birth in multiple sclerosis. Acta Neurol Scand, 1992, 85, 107-109.
122. Torrey E.F., Miller J., Rawlings R., Yolken R.H., Seasonal birth patterns of neurological disorders. Neuroepidemiology, 2000, 19, 177-185.
123. Uccelli R., Binazzi A., Altavista P., Belli S., Comba P., Mastrantonio M., Vanacore N., Geographic distribution of amyotrophic lateral sclerosis through motor neuron disease mortality data. Eur J Epidemiol, 2007, 22, 781-790.
124. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Simmons R., Taylor B.V., Butzkueven H., Kilpatrick T., Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ, 2003, 327, 316.
125. van Es M.A., Veldink J.H., Saris C.G., Blauw H.M., van Vught P.W., Birve A., Lemmens R., Schelhaas H.J., Groen E.J., Huisman M.H., van der Kooi A.J., de Visser M., Dahlberg C., Estrada K., Rivadeneira F., Hofman A., Zwarts M.J., van Doormaal P.T., Rujescu D., Strengman E., Giegling I., Muglia P., Tomik B., Slowik A., Uitterlinden A.G., Hendrich C., Waibel S., Meyer T., Ludolph A.C., Glass J.D., Purcell S., Cichon S., Nothen M.M., Wichmann H.E., Schreiber S., Vermeulen S.H., Kiemeney L.A., Wokke J.H., Cronin S., McLaughlin R.L., Hardiman O., Fumoto K., Pasterkamp R.J., Meininger V., Melki J., Leigh P.N., Shaw C.E., Landers J.E., Al-Chalabi A., Brown R.H., Jr., Robberecht W., Andersen P.M., Ophoff R.A., van den Berg L.H., Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet, 2009, 41, 1083-1087.
126. Wang J.Y., Wu J.N., Cherng T.L., Hoffer B.J., Chen H.H., Borlongan C. V., Wang Y., Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res, 2001, 904, 67-75.
127. Wang L., Hara K., Van Baaren J.M., Price J.C., Beecham G.W., Gallins P.J., Whitehead P.L., Wang G., Lu C., Slifer M.A., Zuchner S., Martin E.R., Mash D., Haines J.L., Pericak-Vance M.A., Gilbert J.R., Vitamin D receptor and Alzheimer's disease: a genetic and functional study. Neurobiol Aging, 2012, 33, 1841-1849.
128. 3 target genes. Mol Endocrinol, 2005, 19, 2685-2695.
129. Wang Y., Marling S.J., McKnight S.M., Danielson A.L., Severson K.S., DeLuca H.F., Suppression of experimental autoimmune encephalomyelitis by 300-315 nm ultraviolet light. Arch Biochem Biophys, 2013, 536, 81-86.
130. Wermuth L., von Weitzel-Mudersbach P., Jeune B., A two-fold difference in the age-adjusted prevalences of Parkinson's disease between the island of Als and the Faroe Islands. Eur J Neurol, 2000, 7, 655-660.
131. Wermuth L., Pakkenberg H., Jeune B., High age-adjusted prevalence of Parkinson's disease among Inuits in Greenland. Neurology, 2002, 58, 1422-1425.
132. Wermuth L., Bech S., Petersen M.S., Joensen P., Weihe P., Grandjean P., Prevalence and incidence of Parkinson's disease in The Faroe Islands. Acta Neurol Scand, 2008, 118, 126-131.
133. Woolmore J.A., Stone M., Pye E.M., Partridge J.M., Boggild M., Young C., Jones P.W., Fryer A.A., Hawkins C.P., Strange R.C., Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation. Mult Scler, 2007, 13, 369-375.
134. Yoon K., Buenaga R., Rodan G.A., Tissue specificity and developmental expression of rat osteopontin. Biochem Biophys Res Commun, 1987, 148, 1129-1136.
135. 3 -enriched diet correlates with a decrease of amyloid plaques in the brain of AbetaPP transgenic mice. J Alzheimers Dis, 2011, 25, 295-307.
136. Zhang J., Sokal I., Peskind E.R., Quinn J.F., Jankovic J., Kenney C., Chung K.A., Millard S.P., Nutt J.G., Montine T.J., CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol, 2008, 129, 526-529.